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Background: The development of newer-generation endografts for the endovascular treatment of abdominal aortic
aneurysms has resulted in considerable improvements in clinical performance. However, long-term outcome data are still
scarce. To assess long-term clinical and radiographic outcomes after use of the Talent stent graft, a retrospective analysis
was performed that was based on 165 patients treated with this endograft in Germany between October 1996 and
December 1998.
Methods: Data were collected according to the recommendation of the ad hoc committee for standardized reporting
practices in vascular surgery and were evaluated statistically by using univariate and multivariate analyses.
Results:A total of 165 patients were treated with a Talent endograft in 9German centers before December 31, 1998.Most
were asymptomatic (94.5%), male (97.6%), and treated with a bifurcated graft (86.7%). Two patients (1.2%) died within
30 days, and 28 (17%) died during the follow-up period. The cause of death was aneurysm rupture in one case. Survival
was 95.4%  1.7% at 1 year, 89%  2.6% at 2 years, 78.1%  3.6% at 5 years, and 76.2%  4.1% at 7 years. Patients
classified as American Society of Anesthesiologists grade IV had a significantly lower survival rate (24.9%) than those
classified as American Society of Anesthesiologists grade II and III (91.9% and 77.3%). During a mean follow-up period
of 53.2  20.1 months (range, 1-84 months), 47 secondary procedures were performed in 31 patients (18.8%).
Kaplan-Meier estimates showed a freedom from secondary intervention of 94.7%  1.8%, 81.7%  3.3%, and 77.4% 
3.6% at 1, 3, and 7 years, respectively. The reason for secondary treatment was endograft thrombosis in 10 patients
(6.1%), persisting primary endoleak in 9 (5.5%), late secondary endoleak in 6 (3.6%), graft migration in 3 (1.8%),
aneurysm rupture in 2 (1.2%), and graft infection in 1 (0.6%). Device migration (>10 mm) occurred in seven patients
(4.2%). Other graft changes, such as graft kinking (n  4; 2.4%), fracture of metallic stents (n  2; 1.2%), erosion of the
longitudinal bar (n  2; 1.2%), or modular component separation (n  1; 0.6%), were rare. Follow-up computed
tomographic imaging revealed a decrease of the maximum aneurysm sac diameter (>5 mm) in 106 (64.2%) patients and
an increase in 14 (8.5%) patients. The mean aneurysm diameter significantly decreased (P<.001). Of the factors recorded
at baseline, only endoleaks showed a significant correlation with the risk of aneurysm increase during follow-up
(P<.001). Adverse anatomy (neck diameter >28 mm, neck length <15 mm, and ’5 patent aortic branches) did not
adversely influence the aneurysm shrinkage rate, the risk for a secondary procedure, or the clinical success rate. A
significantly higher rate of clinical success (P < .05) was observed in patients older than 65 years of age.
Conclusions: Implantation of the Talent endograft device is a safe and effective alternative to open surgery for exclusion
of abdominal aortic aneurysm. In comparison with first-generation grafts, the device showed superior durability for as
long as 5 to 7 years after implantation. Even if prototypes of the Talent device were implanted in this study, the graft was
also successfully used in most patients, even in those with adverse anatomy. Because improvements of the endograft have
been made to address connecting bar breaks, a lower incidence of graft limb occlusion can be expected in the future.
(J Vasc Surg 2006;43:277-84.)Numerous studies have demonstrated the feasibility of
endoluminal endograft techniques in the treatment of ab-
dominal aortic aneurysm (AAA).1-4 Nevertheless, whether
endovascular aneurysm repair (EVAR) is experimental or is
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doi:10.1016/j.jvs.2005.09.037an acceptable treatment remains a subject of debate. Be-
cause of the high rate of complications,5,6 including AAA
rupture,7 the long-term results after EVAR continue to be
a topic of concern.
This skepticism is based on results obtained with first-
generation grafts. Multicenter registry data, eg, Eurostar,8
also include results with grafts that are no longer available
because of the high rate of device failure. Recently pub-
lished studies9,10 have, however, demonstrated that the
outcome after EVAR is also device specific.
Implantation of the Talent AAA (Medtronic, Santa
Rosa, California) endograft system has proven to be a safe
and effective alternative to open surgery for the exclusion of
AAA,11-13 with comparable mortality and reductions in
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clinical use since late 1995, few data on long-term clinical
outcomes are available. To assess the long-term clinical and
radiographic results after implantation of a current self-
expanding endograft, a retrospective analysis was per-
formed in patients treated with a Talent endograft in Ger-
many before 1999.
METHODS
Patients treated with a Talent endograft for AAA be-
tween October 1996 and December 1998 were included in
the study. Nine of the 11 vascular centers in Germany
(Appendix) that had early experience with the Talent en-
dograft participated in this study.
Data collection and definition of the study end points
were performed according to the recommendations of the
Ad Hoc Committee for Standardized Reporting Practices
in Vascular Surgery of the Society for Vascular Surgery/
American Association for Vascular Surgery.14 These in-
cluded information on patient characteristics; procedural
data; preoperative arterial anatomy based on computed
tomography (CT) and angiography; graft data; frequency
of endoleaks and conversion to open surgery; postoperative
interventions; postoperative changes in aneurysm mor-
phology and graft structural integrity, shape, and position;
and postoperative patient outcome. Because the schedules
for maintaining follow-up depended largely on the recruit-
ing centers, only long-term data were collected and in-
cluded in the analysis. According to the protocol, clinical
findings, CT scan, and plain abdominal radiograph studies
of the graft were performed. Only radiographic studies
performed beyond 2 years after the procedure were used.
According to the standards for EVAR, the following pa-
rameters of clinical outcome were reported: early and late
survival rate, rupture-free survival, freedom from secondary
procedure, and clinical success (primary, assisted, and sec-
ondary). Adverse neck anatomy was defined as the presence
of an aneurysm neck less than 15 mm long or more than 28
mm in diameter or reversed conical or bulging morphol-
ogy. Clinical success was defined as a successful deployment
of the endovascular graft in the absence of type I or type III
endoleak; a patent endovascular graft without twists, kinks,
or obstructions; and a lack of aneurysm-related death,
aneurysm expansion (diameter 5 mm), graft dilation or
migration, failure of device integrity, aneurysm rupture
(procedure-related or late), and conversion to open repair.
If catheter-based or surgical interventions, including con-
versions, were needed, the situation was defined as assisted
primary or secondary clinical success.
Statistical analysis was performed with SPSS software
(version 11.0.1; SPSS Inc, Chicago, IL). Patient baseline
characteristics, arterial anatomy, and procedural data were
correlated with clinical and technical results by using uni-
variate analysis. The 2 and the Fisher exact test were used
to analyze discrete variables; the Mann-Whitney test, to
analyze continuous variables; and the Wilcoxon test, to
compare preoperative and postoperative findings. Multi-
variate analysis was used to determine the influence ofdifferent variables on mortality, complications, and aneu-
rysm size changes. The Kaplan-Meier method was used to
assess the cumulative rates of survival and to determine the
influence of different variables on mortality, complications,
and aneurysm size changes. The end points for data collec-
tion/observation were death, explantation of the graft, or
end of follow-up. The log-rank test was used for estimating
the effect of variables on the clinical outcome. Categorical
variables are expressed as frequency and percentage,
whereas continuous variables are presented as mean  SD.
P.05 was considered statistically significant.
RESULTS
A total of 165 patients (age, 69.2  8.8 years) were
treated for AAA with a Talent endograft. Twelve patients
(7.2%) were lost to follow-up. They were alive but did not
come to follow-up examination for different reasons. Their
data were included only for short-term analysis. Most were
asymptomatic (n  156; 94.5%), male (n  161; 97.6%),
and treated with a bifurcated graft (n  143; 86.7%). The
physical status of enrolled patients was assessed by using the
American Society of Anesthesiologists (ASA) guidelines.
Most patients (n  103; 62.4%) were classified as ASA
grade III. Seventeen patients (10.3%) were at high risk
(ASA status IV), and 45 (27.3%) were at low risk (ASA
status II). The mean duration of operation was 133.6 
55.2minutes, with a mean fluoroscopy time of 20.3 16.7
minutes. In 10 patients (6.1%), a blood transfusion was
required.
The mean diameter of the aneurysm sac was 55.9 
10.3 mm, with a proximal neck length of 27.9 10.4 mm
and a neck diameter of 24.6 3.1mm. Themorphology of
the aneurysm neck was straight in 113 (68.5%) patients,
tapered in 31 (18.8%), inverted tapered in 12 (7.3%), and
bulging in 9 (5.4%). According to neck characteristics, the
site of proximal fixation was suprarenal in 141 (85.5%)
patients and infrarenal in 24 (15.5%). The mean diameter
of the endograft was 27.8 3.2 mm for the main body and
14.1  2.0 mm for the iliac leg.
Early outcome. Two patients (1.2%) died within 30
days after the primary implantation. No procedure-related
rupture occurred. Conversion to open repair was necessary
in two patients (1.2%). Twenty type II endoleaks (12.1%)
were observed on the completion angiogram and persisted
during the follow-up in 9 patients (5.5%). The rate of type
II endoleak was significantly higher in the group with more
than three patent aortic branches (n  12; 20.3%) com-
pared with the group that had three or fewer patent
branches (n  7; 7.6%; P .001).
Late mortality and aneurysm-related death.
Twenty-eight patients (17%) died during follow-up (Table
I). The causes of death were cardiac disease (n  15;
53.6%), tumor (n 5; 17.9%), other causes (n 6; 21.4%),
AAA rupture (n  1; 3.6%), and unknown (n  1; 3.6%).
The aneurysm-related mortality was 0.6%. Patient survival
was 95.4%  1.7% at 1 year, 89%  2.6% at 2 years, 78.1%
 3.6% at 5 years, and 76.2%  4.1% at 7 years (Kaplan-
Meier method). The overall mean survival time was 72.0
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classification (10.3%) had a significantly lower survival rate
compared with the ASA grade II and III patients (24.9% vs
91.9% [P  .0005] and 77.3% [P  .005], respectively, at
7 years). When survival rates were stratified according to
age (Fig 2), patients younger than 65 years of age had a
significantly higher survival rate (91.6% vs 68.8%; P  .05)
at 7 years.
Aneurysm expansion. Follow-up CT imaging of 141
patients was available for long-term evaluation. After a
mean follow-up period of 53.2  20.1 months (range,
1-84months), CT imaging revealed a decrease (5mm) in
the maximum aneurysm diameter in 106 patients (75.2%)
and an increase in 14 patients (9.9%). There was no signif-
icant change (5mm) in the maximum aneurysm diameter
in 21 patients (14.9%). Of the 14 patients with aneurysm
expansion, 12 underwent conversion to open repair be-
Table I. Patient outcome
Outcome No. Patients (%)
Aneurysm rupture (procedure-related) 0
Aneurysm rupture (during follow-up) 2 (1.2%)
30-day mortality 2 (1.2%)
Late aneurysm-related mortality 1 (0.6%)
Late mortality 28 (17%)
Lost to follow-up 12 (7.2%)
Clinical success
Primary 99 (73.3%)
Assisted 100 (74.1%)
Secondary 108 (80%)
Fig 1. Survival in patients undergoing endovascular repair with
the Talent endograft.cause of endoleak type I (n 6), endoleak type II (n 4),and rupture (n  2). Two patients are under continuous
follow-up. For the study group overall, the mean aneurysm
diameter significantly decreased to 46.4  13.3 mm (P 
.001), whereas the aneurysm neck diameter increased to
25.1 8.8 mm (P .001). None of the factors recorded at
baseline—ie, age, neck diameter and length, number of
patent aortic branches, endograft design, or preoperative
sac diameter—had a significant correlation with the shrink-
age of the aneurysm during follow-up (Table II).
The evidence of any endoleak was associated with a
significantly higher rate of increased aneurysm sac diameter
during follow-up (P  .001). To investigate the role of
migration with and without endoleak on postoperative
AAA diameter, four groups were built (Table III). A total
of 140 patients with complete CT scan studies performed
before and at least 2 years after the graft implantation were
included in the evaluation. Even though the subgroups
were too small for statistical testing, it is of interest that
three patients had an increase in the diameter of the aneu-
rysm sac in the absence of migration or endoleak. This
finding suggests endotension as a possible mechanism for
aneurysm growth. Three patients with evidence of migra-
tion but without endoleak exhibited a decrease in the
maximum diameter of the aneurysm sac on follow-up,
probably because they were treated by endovascular tech-
niques early enough (Fig 3).
Graft migration and failure of device integrity.
Distal migration of the proximal portion of the endograft
by more than 1 cm occurred in seven (4.2%) cases. In three
of these cases, proximal migration of the distal position of
Fig 2. Survival function (Cox regression) of patients treated with
the Talent endograft for abdominal aortic aneurysm by using the
American Society of Anesthesiologists status as a covariate, strati-
fied by age greater than 65 years and 65 years or younger.the device was also detected. Four patients underwent
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fully by endovascular techniques. Retrospective analysis of
the baseline data showed as a reason for migration minimal
oversizing of the proximal portion of the endograft in two
patients, reversed conical neck morphology in two, signif-
icant neck diameter increase (7 and 8 mm) in two, and low
positioning of the endograft in one. Abdominal plain ra-
diographs showed changes of structural integrity in four
cases (2.4%), with fracture of the stent and of the longitu-
dinal bar in two cases each. In one patient, the fracture of
Table II. Postoperative sac diameter changes in relation
to different preoperative baseline parameters
Sac diameter after EVAR,
n (%)
Variable Decreased
Unchanged or
increased
Sac diameter before EVAR
(n  140)
60 mm 81 (75.0) 27 (25.0)
60 mm 24 (75.0) 8 (25.0)
Neck diameter before EVAR
(n  139)*
28 mm 91 (73.4) 33 (26.6)
28 mm 13 (86.7) 2 (13.3)
Neck length before EVAR
(n  139)*
15 mm 5 (100.0) 0
15 mm 99 (73.9) 35 (26.1)
Age (n  140)
65 y 36 (73.5) 13 (26.5)
65 y 69 (75.8) 22 (24.2)
Patent aortic branches (n 
116)†
3 61 (79.2) 16 (20.8)
3 26 (66.7) 13 (33.3)
5 76 (73.1) 28 (26.9)
5 11 (91.7) 1 (8.3)
Graft design (n  140)
Bifurcated 89 (73.6) 32 (26.4)
Tube or AUI 16 (84.2) 3 (15.8)
EVAR, Endovascular aneurysm repair; AUI, aortouni-iliac.
*One patient was excluded because postoperative neck measurements were
not available.
†Twenty-four patients without exact identification of aortic side branches on
angiography were excluded.
Table III. Changes of maximal abdominal aortic
aneurysm diameter after endovascular repair according to
the presence of endoleak or migration
Aneurysm sac diameter, n (%)
Variable Decreased Unchanged Increased
Endoleak, migration 2 (50.0) 0 2 (50.0)
Endoleak, no migration 15 (46.9) 8 (25.0) 9 (28.1)
Migration, no endoleak 3 (100.0) 0 0
No migration, no
endoleak 85 (84.2) 13 (12.9) 3 (3.0)the longitudinal bar caused graft limb thrombosis, whichwas treated by surgery. The other changes were not severe
enough to warrant treatment: kinking of the graft (30°)
was observed in four patients (2.4%), and dilation of the
graft 20% was observed in one.
Secondary procedures. During follow-up, at least 1
secondary procedure was performed in 31 patients (18.8%).
Kaplan-Meier estimates showed a risk for secondary inter-
vention of 94.7% 1.8%, 81.7% 3.3%, and 77.4% 3.6%
at 1, 3, and 7 years, respectively (Fig 4). There was no
difference in the rate of secondary procedures performed in
patients with adverse neck anatomy (15.8%) compared with
the rate in those with favorable anatomy (21.7%). The
indications for secondary treatment were endograft throm-
bosis in 10 patients (6.1%), persisting primary endoleak in 9
(5.5%), late secondary endoleak in 6 (3.6%), graft migration
in 3 (1.8%), aneurysm rupture in 2 (1.2%), and graft infec-
tion in 1 (0.6%).
Late conversion to open repair was necessary in 13
patients (7.9%). The indication for late conversion was
endoleak type I in six patients, endoleak type II in four,
aneurysm rupture in two, and infection in one. Other
surgical interventions, such as thrombectomies and cross-
over bypass grafts, were performed because of graft limb
occlusion in 10 patients (6.1%). In four cases, thrombec-
tomy was performed before the graft was explanted. All
cases with endograft thrombosis were previously treated
with a bifurcated graft. Because of the small number of
patients treated with an aortouni-iliac or tube graft (n 
22), the risk of graft thrombosis did not statistically corre-
late with the graft design (bifurcated vs nonbifurcated).
One or more additional catheter-based interventions were
performed in 10 patients, including implantation of a prox-
imal (3/165; 1.8%) or distal (6/165; 3.6%) cuff, branch
embolization (8/165; 4.8%), and balloon angioplasty or
stenting (5/165; 3.0%).
Clinical success. Because this study deals with long-
term results, only 135 patients with complete clinical find-
ings, CT scans, and plain abdominal radiograph studies of
the graft performed before and beyond 2 years after the
procedure were included for the evaluation of clinical suc-
cess. At follow-up, 99 patients had a successful graft im-
plantation, thus resulting in a primary clinical success rate of
73.3%. This was increased to 74.1% by the use of catheter-
based techniques (n  100; assisted clinical success) and
was further increased to 80% by surgical interventions (n
108; secondary clinical success). The reasons for clinical
failure were operative mortality (n  2), aneurysm-related
death (n  1), aneurysm rupture (n  2), early and late
conversion to open repair (n 15), aneurysm expansion (n
 14), type I endoleak (n 6), graft thrombosis (n 10),
graft migration (n  7), failure of device integrity (n  4),
graft dilation (n 1), and graft infection (n 1). Twenty-
two patients had a single reason for clinical failure. In 14
patients, a combination of the above-listed reasons was
found (Table IV). Of the factors recorded at baseline that
were analyzed with multivariate logistic regression analysis,
only age 65 years or older was a positive independent
predictor of clinical success.
raft tr
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As a result of progress made in endovascular therapy, it
has been possible to treat AAA without major surgical
procedures, thus reducing the risks associated with laparot-
omy, aortic clamping, blood transfusion, and incisional
hernia, as well as to decrease recovery time.4,15-17 The
Fig 3. Migration of a Talent stent g
Fig 4. Freedom from a secondary procedure after treatment of an
abdominal aortic aneurysm with a Talent endograft.endovascular approach consists of transfemoral introduc-tion of a metallic stent coupled with a vascular graft. Re-
cently, it has become possible to perform the procedure
entirely percutaneously with no requirement for surgical
cut-down.18 Recently published randomized trials compar-
ing conventional and EVAR of AAA have shown a clear
short-term survival benefit for EVAR,19,20 as well as a lower
rate of systemic complications, reduced blood loss, and
shorter hospital stays. The 2-year results of the EVAR trial
1 and the Dutch Randomized Endovascular Aneurysm
Management (DREAM) trial show higher aneurysm-re-
lated survival for the EVAR but more complications and
reinterventions. The advantage of EVAR over open repair
has been accounted for by events occurring in the periop-
erative period, and there is still uncertainty regarding the
long-term outcome of EVAR because aneurysm rup-
tures,7,21,22 graft migration, and modular separation5,6,23
have been reported. These complications have been ob-
served particularly in patients treated with earlier devices
eated with a proximal extender cuff.
Table IV. Patients with multiple reasons for clinical
failure
Variable n
Type I endoleak  aneurysm expansion  conversion 2
Aneurysm rupture  aneurysm expansion  conversion 2
Type I endoleak  aneurysm expansion  migration 
conversion 4
Graft thrombosis  type II endoleak  aneurysm
expansion  conversion 4
Graft infection  conversion 1
Graft thrombosis  fracture of the longitudinal bar 1
Total 14and those with infrarenal anchoring of the endograft.
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dograft system composed of serpentine-shaped nitinol
stents inlaid in a woven polyester fabric. The stents are
spaced along a full-length nitinol spine. The latter provides
column strength to a graft that is otherwise flexible to
accommodate aortoiliac angulations. A 15-mm-long un-
covered stent at the proximal end allows transrenal or
suprarenal fixation. The graft has been used in the treat-
ment of AAA in more than 25,000 patients worldwide, and
some studies have confirmed that a high degree of technical
and procedural success can be achieved.9,11,12,24,25 How-
ever, until now, no multicenter study examining the long-
term effectiveness of the Talent endograft for the treatment
of AAA has been published.
In this series, both early mortality and aneurysm-re-
lated death were low. The conversion rate to an open
procedure was high but not associated withmortality in this
study. The indication to conversion was, in 10 of 13
patients, an endoleak, which can be treated today with
endovascular techniques. However, the liberal indication
to open conversion could explain the low rupture rate
(1.2%) and aneurysm-related mortality (0.6%) observed
after a follow-up of 7 years. Moreover, patient survival at 5
and 7 years was lower than that reported after conventional
repair in retrospective studies.26-29 As expected, it was
significantly lower in patients with an ASA IV classification
and in patients older than 65 years of age: this also reflects
the role of patient selection in clinical outcome.
In this study, CT imaging showed a decrease of the
maximum aneurysm diameter in 75.2% of the patients.
None of the parameters assessed at baseline affected the
change in sac diameter during follow-up. Adverse neck
morphology and the number of patent aortic branches did
not influence the long-term results in terms of aneurysm
shrinkage or technical and clinical success. The availability
of larger sizes and the option for transrenal fixation led to
an early use of the Talent device for the treatment of
patients with challenging anatomy. Concerns regarding
migration after enlargement of a wide and short aneurysm
neck were the justification for excluding patients from
endovascular treatment with other devices. In this report,
30 patients (18%) with a wide (28 mm) and 15 (9%) with
a short (15 mm) aneurysm neck were also included, and
the rates of technical and clinical success, as well as the rate
of sac shrinkage, in this high-risk patient group were similar
to those of patients at a lower risk. These results also
compare well to those of other studies30,31 obtained by
using endografts with a suprarenal fixation. Reductions in
the aneurysm sac diameter were observed in most patients,
with minimal changes in graft structural integrity and
shape. Adverse device reconfiguration, as observed in pa-
tients treated with other endografts,5,6 was rarely detected,
even as long as 5 to 7 years after implantation of the Talent
device. Remodeling of the aorta after shrinkage of the
aneurysm sac did not have a negative effect on graft align-
ment in the aneurysm.
In 10 patients (6.1%), 1 or multiple secondary proce-
dures were performed for obstruction of 1 limb of a bifur-cated graft. Connecting bar fracture was the reason for this
complication in two patients, and kinking of the graft in
tortuous iliac vessels was the reason in four. To allow better
conformability and to reduce the rate of graft kinking and
limb thrombosis, the lateral spine along the ipsilateral bi-
furcation limb was moved to the medial position. This
improvement to the device and a better delivery system
(Xcelerant, Medtronic, Santa Rosa, California) are now
part of the available platform and should decrease the risk of
device-related graft thrombosis in the future.
Migration of the graft was detected during follow-up in
seven cases (4.2%). Insufficient oversizing of the endograft,
reversed conical neck morphology, a significant neck diam-
eter increase, and low positioning of the endograft were the
reason for migration in these patients. It is interesting to
note that migration in the absence of endoleak neither
negatively affected aneurysm shrinkage nor led to rupture.
The migrations were detected early enough to be treated
before complications occurred. The migration rate was low
compared with those of earlier endografts5,6,8 and with
those of grafts placed with infrarenal fixation.32,33 A single-
institution analysis correlating the attributes of five en-
dografts with clinical outcome10 showed an overall migra-
tion rate of 3.6% at 1 year. The migration rate of the Talent
device in that study was 0%.
As has been demonstrated in other studies, the most
important risk factor for an increase in aneurysm size was
evidence of endoleak.34 In this series, 18.8% of patients
underwent at least one secondary procedure. Similar results
were reported by Cao et al26 at 7 years and by Verhoeven et
al35 at 3 years, but they found lower conversion rates (4.9%
and 3%, respectively) than we did (9.1%).
Even though a comparison with the long-term results
of other stent grafts or of open repair is difficult, aneurysm-
related mortality, rupture rate, and changes in graft struc-
ture and position compare favorably to the results found in
other studies.26-29,36-38The long-term results obtained
with the Talent endograft justify its use. The high reinter-
vention rate, however, underscores the importance of a
lifelong follow-up.
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The Talent endograft (Medtronic, Santa Rosa, Calif), which
has been available since 1995, is the abdominal aortic aneurysm
(AAA) endograft system that has been the longest sold under the
same name. In the past, a number of modifications have been
established to address problems of wire breaks. The changes in the
nitinol surface, the shape of the stent apexes, and the position of
the longitudinal bar were successful in enhancing metal fatigue
performance at bench testing and at radiographic follow-up assess-
ment in clinical studies.1,2 Not withstanding these improvements,
the basic design of the current Talent low profile system (LPS) is
identical to the previous generation.
The group of German collaborators, who have detailed their
experience with the Talent device during the first years of its
availability up to December 1998, are to be commended for their
effort. A mean follow-up period of 53 months after endovascular
aneurysm repair (EVAR) is not frequently reported, and for this
reason, this study may be of particular interest. A number of
weaknesses can be noted, however.
First, the study has a retrospective design, which inevitably
causes loss of important details. For instance, although the authors
reported the proportion of infrarenal necks that were wider or
shorter than recommended guidelines, other details such as neck
angulation or thrombus lining might have provided a more com-
plete picture. These omissions precluded assessment of the effect of
adverse anatomy on the long-term outcome of endovascular treat-
ment. The Talent endograft has been, during the many years of its
existence, the favorite choice of many interventionalists in patients
with more hostile anatomy. The device brand had the largest
available size range, and in addition, the option to order custom-
made devices for even more extreme conditions was available. A
long-term follow-up study as the present one should have provided
a comparison of the outcome in patients with complicated and
uncomplicated anatomic features.
Second, adverse events such as migration, endoleaks, and
secondary interventions were infrequent in this series. It appeared,
however, that these good results were at least partly due to consid-cently published study by EUROSTAR shows that the neck length
was15 mm in 16% vs 3.6%, and the aneurysm diameter was60
mm in 43% vs 23% in the EUROSTAR-Talent group and the
present series, respectively.3 These differences indicate the selec-
tion of relatively uncomplicated cases, whichmay explain the good,
long-term outcome in this series. It certainly would have been
interesting, when the authors had disclosed the proportion of
patients treated with a Talent endograft relative to all AAA-patients
treated during the study period.
Third, the indication of only the crude rates of device migra-
tion, endoleaks, and kinking or thrombosis of iliac device limbs was
another omission. In particular, when these events can be assessed
in a series with sufficiently long-term follow-up, assessment in
life-table format is indispensable. One would like to know whether
device migration or other problems occurred within the early
postoperative period or after a number of years. This knowledge is
essential for planning an effective and cost-conscious surveillance
schedule after EVAR.
Finally, considering the excellent long-term results obtained,
the authors might have touched upon the performance of the
current generation of stent-grafts, in particularly the Talent LPS
endograft, with a basically similar design after being in use for 10
years. Is this a device that needs to be replaced by a completely
redesigned stent-graft, or is it still up-to-date for the stent-graft
market in 2006? These are important questions, which still need to
be addressed in a future overview.
REFERENCES
1. Criado FJ, Clark NS, McKendrick C, Longway J, Domer GS. Update on
the Talent LPS AAA stent-graft: results with “enhanced Talent”. Semin
Vasc Surg 2003;16:158-65.
2. Espinoza G, RibeiroM, Riguetti C, Ferreira CaramalhoM, Dias Siqueira
Mendes W, Santos SR. Six-year experience with Talent stent-graft repair
of abdominal aortic aneurysms. J Endovasc Ther 2005;12:35-45.
3. Van Marrewijk CJ, Leurs LJ, Vallabhaneni SR, Harris PL, Buth J, Laheij
JF. Risk-adjusted outcome analysis of endovascular abdominal aortic
aneurysma repair in a large population: how do stent-grafts compare? J
Endovasc Ther 2005;12:417-29.
